Kagone T S, Hien H, Meda N, Diagbouga P S, Sawadogo A, Drabo J, Peeters M, Vergne L, Delaporte E, De Souza C, Gbeassor M, Simpore J
Centre MURAZ Bobo-Dioulasso, Burkina Faso.
Pak J Biol Sci. 2011 Mar 15;14(6):392-8. doi: 10.3923/pjbs.2011.392.398.
The purposes of this study were: (1) to describe the genetic variability of HIV strains found in Burkina Faso, (2) to characterize non-B HIV strains mutation profiles selected by ARVs and (3) to detect possible resistances induced by ARV drugs. From 30 October 2002 to 20 November 2003, 132 HIV 1-positive patients taking Highly Active Antiretroviral Therapy (HAART) for more than one year in Bobo-Dioulasso and Ouagadougou were included. T-CD4+ lymphocytes count was done using Dynabeads technique while genotypic test and ARV-resistance tests were conducted using Pol sequencing that codes for reverse transcriptase reverse, integrase and protease. Due to undetectable viremia, 86 samples out of 132 could not be characterized. Whereas in the 46 others that had a viral load exceeding 1000 copies mL(-1), the following HIV-1 subtypes were identified: CRF06 (54,55%); CRF02(38,63%); CRF01 (4,55%) and subtype A (2,27%). In addition, several mutations related to PI, NRTI and NNRTI resistance were isolated in 27 samples. This study found a huge genetic HIV-1 polymorphism in Burkina Faso. The level of acquired resistance to ARV after one year of treatment amounted 20.4%. These results clearly show that there is imperative need to set up an ARV resistance surveillance network in Burkina Faso to guide treatment strategies and follow the extension of the phenomenon in the country.
(1)描述在布基纳法索发现的HIV毒株的基因变异性;(2)表征由抗逆转录病毒药物(ARV)选择的非B型HIV毒株的突变谱;(3)检测ARV药物诱导的可能耐药性。从2002年10月30日至2003年11月20日,纳入了132名在博博迪乌拉索和瓦加杜古接受高效抗逆转录病毒治疗(HAART)超过一年的HIV-1阳性患者。使用磁珠技术进行T-CD4+淋巴细胞计数,而基因分型检测和ARV耐药性检测则使用编码逆转录酶、整合酶和蛋白酶的Pol序列进行。由于病毒血症检测不到,132个样本中有86个无法进行表征。而在其他46个病毒载量超过1000拷贝/mL(-1)的样本中,鉴定出了以下HIV-1亚型:CRF06(54.55%);CRF02(38.63%);CRF01(4.55%)和A亚型(2.27%)。此外,在27个样本中分离出了与蛋白酶抑制剂(PI)、核苷类逆转录酶抑制剂(NRTI)和非核苷类逆转录酶抑制剂(NNRTI)耐药相关的几种突变。本研究发现布基纳法索存在巨大的HIV-1基因多态性。治疗一年后获得性ARV耐药水平为20.4%。这些结果清楚地表明,布基纳法索迫切需要建立一个ARV耐药监测网络,以指导治疗策略并跟踪该国该现象的蔓延情况。